Envestnet Asset Management Inc. Buys 71,684 Shares of Novo Nordisk A/S $NVO

Key Points

• Envestnet Asset Management increased its Novo Nordisk stake by 1.8% in the second quarter, acquiring 71,684 shares and bringing its total holdings to 4.03 million shares valued at approximately $193.3 million.
• Novo is targeting more than $23 billion in pipeline sales by 2035 and plans to launch several potential blockbuster drugs, but investors remain concerned about slowing Wegovy and Ozempic growth, patent expirations, pricing pressure, and competition from Eli Lilly.
• Analyst sentiment remains cautious: Novo has an overall “Hold” consensus rating with a $64.94 target price, while the stock recently traded near $38.60—well below its 52-week high of $64.16.

Envestnet Asset Management Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 1.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,031,114 shares of the company's stock after acquiring an additional 71,684 shares during the period. Envestnet Asset Management Inc. owned about 0.09% of Novo Nordisk A/S worth $193,250,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Franklin Resources Inc. grew its stake in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company's stock valued at $748,064,000 after buying an additional 717,719 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $287,660,000. State Street Corp raised its holdings in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company's stock valued at $284,565,000 after purchasing an additional 32,641 shares during the period. Royal Bank of Canada grew its holdings in Novo Nordisk A/S by 3.2% during the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company's stock worth $166,396,000 after purchasing an additional 141,376 shares during the period. Finally, Natixis Advisors LLC grew its holdings in Novo Nordisk A/S by 4.1% during the fourth quarter. Natixis Advisors LLC now owns 2,661,238 shares of the company's stock worth $135,404,000 after purchasing an additional 105,703 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo set a goal of generating more than DKK 150 billion—roughly $23 billion—in pipeline sales by 2035 and aims to launch more than five potential multiblockbuster medicines by 2030. Management expects bolt-on acquisitions and new products to reduce reliance on Wegovy and Ozempic after patent protection begins to expire. Novo Nordisk Sets Pipeline Sales Target Above $23 Billion By 2035
• Positive Sentiment: Encouraging clinical and regulatory news includes positive CagriSema trial results, strong quarter-over-quarter growth for the Wegovy pill, and Singapore approval for Wegovy in certain liver-related uses. Rare-disease candidates Frehemgo and Sogroya also received positive European regulatory opinions. Novo's CagriSema Delivers Superior Weight Loss Versus Tirzepatide
• Neutral Sentiment: CEO Mike Doustdar said Novo is open to eventually replacing its American depositary receipts with a direct New York listing. Such a move could improve U.S. investor access and visibility, but management said it is not currently pursuing a listing change. Novo Nordisk Open to New York Listing Upgrade
• Negative Sentiment: Investors viewed the capital-markets update as lacking near-term detail and reacted negatively to management’s warning about Wegovy and Ozempic growth. Analysts remain concerned that Eli Lilly is gaining ground in the GLP-1 market and that the new pipeline targets will take years to translate into revenue. Novo's New Strategy Hinges on Investor Trust
• Negative Sentiment: Upcoming semaglutide patent cliffs, pricing pressure, and uncertainty over the durability of Novo’s competitive position have outweighed the stock’s inexpensive valuation. Commentary that a cheap earnings multiple cannot compensate for weak growth has reinforced the selloff. Novo Nordisk CEO Delivered a Warning

Analyst Ratings Changes

Several analysts have issued reports on NVO shares. Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. HSBC restated a "hold" rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a "hold" rating to a "sell" rating in a research note on Thursday, August 27th. Finally, Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $64.94.

Novo Nordisk A/S Stock Up 1.1%

NVO opened at $38.60 on Friday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market capitalization of $172.37 billion, a P/E ratio of 9.44, a P/E/G ratio of 1.30 and a beta of 0.74. The stock has a fifty day moving average of $45.95 and a 200-day moving average of $43.87.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $11.98 billion for the quarter. On average, equities analysts expect that Novo Nordisk A/S will post 3.52 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a $0.5786 dividend. This represents a dividend yield of 258.0%. This is a decrease from Novo Nordisk A/S's previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio is presently 20.05%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.